Global Information
회사소개 | 문의 | 비교리스트

Millennium Pharmaceuticals, Inc. : 제품 파이프라인 리뷰

Millennium Pharmaceuticals Inc - Product Pipeline Review - 2016

리서치사 Global Markets Direct
발행일 2016년 12월 상품 코드 251690
페이지 정보 영문 61 Pages
가격
US $ 1,500 ₩ 1,823,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,646,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,500 ₩ 5,470,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


Millennium Pharmaceuticals, Inc. : 제품 파이프라인 리뷰 Millennium Pharmaceuticals Inc - Product Pipeline Review - 2016
발행일 : 2016년 12월 페이지 정보 : 영문 61 Pages

Millennium Pharmaceuticals, Inc.는 암 치료제의 연구개발 및 상품화를 담당하는 바이오 제약회사입니다. 주력 제품인 Velcade(bortezomib)는 다발성 골수종과 재발성 맨틀 세포 림프종의 치료를 위해 개발되었습니다. Millennium Pharmaceuticals, Inc.의 제품에는 다양한 종류의 암을 타겟으로 한 15 종류 이상의 종양 임상시험 화합물이 있습니다.

Millennium Pharmaceuticals, Inc.의 치료제 개발 파이프라인 현황과 각 개발 단계 비교 분석, 약제 표적, 작용기서, 투여 경로, 분자 종류별 치료제 평가, 최신 기업 뉴스와 발표, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 전해드립니다.

Millennium Pharmaceuticals, Inc.의 기본 정보

Millennium Pharmaceuticals, Inc.의 개요

  • 주요 정보
  • 기업 정보

Millennium Pharmaceuticals, Inc. : R&D 개요

  • 주요 치료 범위

Millennium Pharmaceuticals, Inc. : 파이프라인 리뷰

  • 개발 단계별 파이프라인 제품
  • 단독요법
  • 파트너 제품
    • 파트너 제품/병용요법 모달리티
  • 아웃 라이선스 제품
    • 아웃 라이선스 제품/병용요법 모달리티

Millennium Pharmaceuticals, Inc. : 파이프라인 제품 개요

  • 최종 단계 파이프라인 제품
    • 등록전 제품/병용요법 모달리티
    • 출원이 각하된/취하된 제품/병용요법 모달리티
    • 제III상 제품/병용요법 모달리티
  • 임상 단계 파이프라인 제품
    • 제II상 제품/병용요법 모달리티
    • 제I상 제품/병용요법 모달리티
  • 초기 단계 파이프라인 제품
    • 전임상 제품/병용요법 모달리티
    • 디스커버리 제품/병용요법 모달리티

Millennium Pharmaceuticals, Inc. : 치료제 개요

  • bortezomib
  • alisertib
  • brentuximab vedotin
  • ixazomib citrate
  • MLN-0128
  • MLN-2480
  • orteronel
  • MLN-0264
  • MLN-1117
  • MLN-7243
  • pevonedistat hydrochloride
  • TAK-659
  • TAK-733
  • Small Molecules to Inhibit Histone Deacetylase 6 for Cacner

Millennium Pharmaceuticals, Inc. : 파이프라인 분석

  • 표적별
  • 투여 경로별
  • 분자 종류별
  • 작용기서별

Millennium Pharmaceuticals, Inc. : 최근의 파이프라인 동향

Millennium Pharmaceuticals, Inc. : 휴지중인 프로젝트

Millennium Pharmaceuticals, Inc. : 개발이 중지된 파이프라인 제품

  • 개발이 중지된 파이프라인 제품 개요
    • alisertib
    • betrixaban
    • bortezomib
    • HuL-2G7
    • orteronel
    • TAK-441
    • TAK-448
    • TAK-901
    • TAK-960
    • tandutinib

Millennium Pharmaceuticals, Inc. : 기업 발표

Millennium Pharmaceuticals, Inc. : 본사 및 자회사 소재지

부록

도표

KSM 14.08.13

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Summary:

Global Markets Direct's, 'Millennium Pharmaceuticals Inc - Product Pipeline Review - 2016', provides an overview of the Millennium Pharmaceuticals Inc's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Millennium Pharmaceuticals Inc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the pipeline therapeutic landscape of Millennium Pharmaceuticals Inc
  • The report provides overview of Millennium Pharmaceuticals Inc including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Millennium Pharmaceuticals Inc's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Millennium Pharmaceuticals Inc's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy:

  • Evaluate Millennium Pharmaceuticals Inc's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Millennium Pharmaceuticals Inc
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Millennium Pharmaceuticals Inc's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Millennium Pharmaceuticals Inc Snapshot
    • Millennium Pharmaceuticals Inc Overview
    • Key Facts
  • Millennium Pharmaceuticals Inc - Research and Development Overview
    • Key Therapeutic Areas
  • Millennium Pharmaceuticals Inc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Millennium Pharmaceuticals Inc - Pipeline Products Glance
    • Millennium Pharmaceuticals Inc - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Millennium Pharmaceuticals Inc - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Millennium Pharmaceuticals Inc - Drug Profiles
    • alisertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bortezomib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • orteronel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pevonedistat hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sapanisertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • serabelisib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Histone Deacetylase 6 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-243 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-580 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-659 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-931 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Millennium Pharmaceuticals Inc - Pipeline Analysis
    • Millennium Pharmaceuticals Inc - Pipeline Products by Target
    • Millennium Pharmaceuticals Inc - Pipeline Products by Route of Administration
    • Millennium Pharmaceuticals Inc - Pipeline Products by Molecule Type
    • Millennium Pharmaceuticals Inc - Pipeline Products by Mechanism of Action
  • Millennium Pharmaceuticals Inc - Dormant Projects
  • Millennium Pharmaceuticals Inc - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • alisertib
      • betrixaban
      • bortezomib
      • HuL-2G7
      • indusatumab vedotin
      • IPI-443
      • orteronel
      • TAK-441
      • TAK-733
      • TAK-901
      • TAK-960
      • tandutinib
  • Millennium Pharmaceuticals Inc - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Millennium Pharmaceuticals Inc, Key Facts
  • Millennium Pharmaceuticals Inc - Pipeline by Indication, 2016
  • Millennium Pharmaceuticals Inc - Pipeline by Stage of Development, 2016
  • Millennium Pharmaceuticals Inc - Monotherapy Products in Pipeline, 2016
  • Millennium Pharmaceuticals Inc - Out-Licensed Products in Pipeline, 2016
  • Millennium Pharmaceuticals Inc - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Millennium Pharmaceuticals Inc - Phase II, 2016
  • Millennium Pharmaceuticals Inc - Phase I, 2016
  • Millennium Pharmaceuticals Inc - Preclinical, 2016
  • Millennium Pharmaceuticals Inc - Discovery, 2016
  • Millennium Pharmaceuticals Inc - Pipeline by Target, 2016
  • Millennium Pharmaceuticals Inc - Pipeline by Route of Administration, 2016
  • Millennium Pharmaceuticals Inc - Pipeline by Molecule Type, 2016
  • Millennium Pharmaceuticals Inc - Pipeline Products by Mechanism of Action, 2016
  • Millennium Pharmaceuticals Inc - Dormant Developmental Projects,2016
  • Millennium Pharmaceuticals Inc - Discontinued Pipeline Products, 2016

List of Figures

  • Millennium Pharmaceuticals Inc - Pipeline by Top 10 Indication, 2016
  • Millennium Pharmaceuticals Inc - Pipeline by Stage of Development, 2016
  • Millennium Pharmaceuticals Inc - Monotherapy Products in Pipeline, 2016
  • Millennium Pharmaceuticals Inc - Out-Licensed Products in Pipeline, 2016
  • Millennium Pharmaceuticals Inc - Pipeline by Top 10 Target, 2016
  • Millennium Pharmaceuticals Inc - Pipeline by Route of Administration, 2016
  • Millennium Pharmaceuticals Inc - Pipeline by Molecule Type, 2016
  • Millennium Pharmaceuticals Inc - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top
전화 문의
F A Q